In 598 patients with IPF, inhaled treprostinil slowed FVC decline vs placebo at 52 weeks (median change -43.3 vs -196.2 ml; difference 130.1 ml). Clinical worsening (secondary) 31.8% vs 44.5% (HR 0.67); cough 54.8% vs 33.1%.
RCTn = 598
Nathan et al. Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis